The recently discovered regulators of G-protein signaling (RGS) proteins potently modulate the functioning of heterotrimeric G-proteins by stimulating the GTPase activity of G-protein ␣ subunits. The mRNAs for numerous subtypes of putative RGS proteins have been identified in mammalian tissues, but little is known about their expression in brain. We performed a systematic survey of the localization of mRNAs encoding nine of these RGSs, RGS3-RGS11, in brain by in situ hybridization. Striking region-specific patterns of expression were observed. Five subtypes, RGS4, RGS7, RGS8, RGS9, and RGS10 mRNAs, are densely expressed in brain, whereas the other subtypes (RGS3, RGS5, RGS6, and RGS11) are expressed at lower density and in more restricted regions. RGS4 mRNA is notable for its dense expression in neocortex, piriform cortex, caudoputamen, and ventrobasal thalamus. RGS8 mRNA is highly expressed in the cerebellar Purkinje cell layer as well as in several midbrain nuclei. RGS9 mRNA is remarkable for its nearly exclusive enrichment in striatal regions. RGS10 mRNA is densely expressed in dentate gyrus granule cells, superficial layers of neocortex, and dorsal raphe. To assess whether the expression of RGS mRNAs can be regulated, we examined the effect of an acute seizure on levels of RGS7, RGS8, and RGS10 mRNAs in hippocampus. Of the three subtypes, changes in RGS10 levels were most pronounced, decreasing by ϳ40% in a timedependent manner in response to a single seizure. These results, which document highly specific patterns of RGS mRNA expression in brain and their ability to be regulated in a dynamic manner, support the view that RGS proteins may play an important role in determining the intensity and specificity of signaling pathways in brain as well as their adaptations to synaptic activity. Key words: seizure; gene expression; striatum; neocortex; GTPase-activating proteins; Sst2; GAIPThe heterotrimeric G-proteins play a critical role in brain signal transduction by coupling extracellular receptors to intracellular signaling pathways. G-proteins are composed of single ␣, ␤, and ␥ subunits. The ␣ subunits are guanine nucleotide-binding proteins that are regulated through cycles of GTP and GDP binding. In the inactive state, the ␣ subunits are bound to GDP. They are activated by G-protein-coupled receptors (bound to ligand), which trigger the dissociation of GDP and the subsequent binding of GTP, which activates the ␣ subunit. The active state is terminated when the intrinsic GTPase activity contained within the ␣ subunit hydrolyzes GTP to GDP (for review, see Neer, 1995).Recently, a newly discovered class of protein, termed regulators of G-protein signaling (RGS) proteins, has been shown to modulate the f unctioning of G-proteins by activating the intrinsic GTPase activity of the ␣ subunits (for review, see Dohlman and Thorner, 1997;Koelle, 1997;Neer, 1997). RGS proteins thereby reduce the duration of the activated GTPbound state of the ␣ subunit, which inhibits G-protein f unction. RGS proteins were first discover...

Background-Cellular hypertrophy requires coordinated regulation of progrowth and antigrowth mechanisms. In cultured neonatal cardiomyocytes, Foxo transcription factors trigger an atrophy-related gene program that counters hypertrophic growth. However, downstream molecular events are not yet well defined. Methods and Results-Here, we report that expression of either Foxo1 or Foxo3 in cardiomyocytes attenuates calcineurin phosphatase activity and inhibits agonist-induced hypertrophic growth. Consistent with these results, Foxo proteins decrease calcineurin phosphatase activity and repress both basal and hypertrophic agonist-induced expression of MCIP1.4, a direct downstream target of the calcineurin/NFAT pathway. Furthermore, hearts from Foxo3-null mice exhibit increased MCIP1.4 abundance and a hypertrophic phenotype with normal systolic function at baseline. Together, these results suggest that Foxo proteins repress cardiac growth at least in part through inhibition of the calcineurin/NFAT pathway. Given that hypertrophic growth of the heart occurs in multiple contexts, our findings also suggest that certain hypertrophic signals are capable of overriding the antigrowth program induced by Foxo. Consistent with this, multiple hypertrophic agonists triggered inactivation of Foxo proteins in cardiomyocytes through a mechanism requiring the PI3K/Akt pathway. In addition, both Foxo1 and Foxo3 are phosphorylated and consequently inactivated in hearts undergoing hypertrophic growth induced by hemodynamic stress. Key Words: angiotensin Ⅲ calcineurin Ⅲ hypertrophy I n response to stress from neurohumoral activation, hypertension, or other myocardial injury, the heart initially compensates with an adaptive hypertrophic increase in mass. The resulting growth and remodeling response alters the balance between protein synthesis and protein degradation. In skeletal muscle, activation of progrowth signaling pathways is accompanied by deactivation of pathways that promote proteolysis. Prominent among the atrophy-inducing pathways are those governed by Forkhead box transcription factors, O subfamily (Foxo). Conclusions-This Clinical Perspective p 1168Foxo transcription factors regulate key physiological functions, including responses to stress, cell-cycle progression, protein degradation, and apoptosis. 1,2 There are 4 mammalian Foxo genes: Foxo1 (FKHR), Foxo3 (FKHRL1), Foxo4 (AFX), and Foxo6. The transcriptional activities of Foxo proteins are governed by posttranslational modifications such as phosphorylation and acetylation. With respect to myocyte growth and remodeling, Foxo proteins induce ubiquitin ligases and promote proteolysis in skeletal muscle. 3,4 In heart, a number of signaling cascades involving transcription factors, kinases, and G-protein-coupled receptors are implicated in the regulation of muscle growth (see reviews 5-7 ). Among these, the calcineurin/nuclear factor of activated T cells (NFAT) pathway has been shown to be a key signaling cascade that promotes cardiac hypertrophy. 8 It has been reported recently...

Miscible-displacement experiments are conducted with perfluorooctanoic acid (PFOA) to determine the contribution of adsorption at the air-water interface to retention during transport in water-unsaturated porous media. Column experiments were conducted with two sands of different diameter at different PFOA input concentrations, water saturations, and pore-water velocities to evaluate the impact of system variables on retardation. The breakthrough curves for unsaturated conditions exhibited greater retardation than those obtained for saturated conditions, demonstrating the significant impact of air-water interfacial adsorption on PFOA retention. Retardation was greater for lower water saturations and smaller grain diameter, consistent with the impact of system conditions on the magnitude of air-water interfacial area in porous media. Retardation was greater for lower input concentrations of PFOA for a given water saturation, consistent with the nonlinear nature of surfactant fluid-fluid interfacial adsorption. Retardation factors predicted using independently determined parameter values compared very well to the measured values. The results showed that adsorption at the air-water interface is a significant source of retention for PFOA, contributing approximately 50-75% of total retention, for the test systems. The significant magnitude of air-water interfacial adsorption measured in this work has ramifications for accurate determination of PFAS migration potential in vadose zones.

Insulin resistance and metabolic syndrome are rapidly expanding public health problems. Acting through the PI3K/Akt pathway, insulin and insulin-like growth factor-1 (IGF-1) inactivate FoxO transcription factors, a class of highly conserved proteins important in numerous physiological functions. However, even as FoxO is a downstream target of insulin, FoxO factors also control upstream signaling elements governing insulin sensitivity and glucose metabolism. Here, we report that sustained activation of either FoxO1 or FoxO3 in cardiac myocytes increases basal levels of Akt phosphorylation and kinase activity. FoxO-activated Akt directly interacts with and phosphorylates FoxO, providing feedback inhibition. We reported previously that FoxO factors attenuate cardiomyocyte calcineurin (PP2B) activity. We now show that calcineurin forms a complex with Akt and inhibition of calcineurin enhances Akt phosphorylation. In addition, FoxO activity suppresses protein phosphatase 2A (PP2A) and disrupts Akt-PP2A and Akt-calcineurin interactions. Repression of Akt-PP2A/B interactions and phosphatase activities contributes, at least in part, to FoxO-dependent increases in Akt phosphorylation and kinase activity. Resveratrol, an activator of Sirt1, increases the transcriptional activity of FoxO1 and triggers Akt phosphorylation in heart. Importantly, FoxO-mediated increases in Akt activity diminish insulin signaling, as manifested by reduced Akt phosphorylation, reduced membrane translocation of Glut4, and decreased insulintriggered glucose uptake. Also, inactivation of the gene coding for FoxO3 enhances insulin-dependent Akt phosphorylation. Taken together, this study demonstrates that changes in FoxO activity have a dose-responsive repressive effect on insulin signaling in cardiomyocytes through inhibition of protein phosphatases, which leads to altered Akt activation, reduced insulin sensitivity, and impaired glucose metabolism.cardiomyocyte ͉ calcineurin ͉ insulin resistance ͉ cardiomyopathy

The protein PCSK9 (proprotein convertase subtilisin/kexin type 9) is a key regulator of low-density lipoprotein receptor (LDLR) levels and cardiovascular health. We have determined the crystal structure of LDLR bound to PCSK9 at neutral pH. The structure shows LDLR in a new extended conformation. The PCSK9 C-terminal domain is solvent exposed, enabling cofactor binding, whereas the catalytic domain and prodomain interact with LDLR epidermal growth factor(A) and b-propeller domains, respectively. Thus, PCSK9 seems to hold LDLR in an extended conformation and to interfere with conformational rearrangements required for LDLR recycling.

A comprehensive compartment model is presented for PFAS retention that incorporates all potential processes relevant for transport in source zones. Miscible-displacement experiments were conducted to investigate separately the impact of adsorption at the air-water and decane- water interfaces on PFAS retention and transport. Two porous media were used, a quartz sand and a soil, and perfluorooctanesulfonic acid (PFOS) was used as the model PFAS. The breakthrough curves for transport under water-unsaturated conditions were shifted noticeably rightward (delayed arrival) compared to the breakthrough curves for saturated conditions, indicating greater retardation due to adsorption at the air-water or decane-water interface. The retardation factor was 7 for PFOS transport in the sand for the air-water system, compared to 1.8 for saturated conditions. PFOS retardation factors for transport in the soil were 7.3 and 3.6 for unsaturated (air-water) vs saturated conditions. Air-water interfacial adsorption is a significant source of retention for PFOS in these two systems, contributing more than 80% of total retention for the sand and 32% for the soil. For the experiments conducted with decane residual emplaced within the sand, adsorption at the decane-water interface contributed more than 70% to total retention for PFOS transport. Methods to determine or estimate key distribution variables are presented for parameterization of the model. Predicted retardation factors were similar to the measured values, indicating that the conceptual model provided adequate representation of the relevant retention processes and that the parameter estimation methods produced reasonable values. The results of this work indicate that adsorption by fluid-fluid interfaces in variably saturated porous media can be a significant retention process for PFAS that should be considered when characterizing their transport and fate behavior in source zones.

Regulators of G-protein signaling (RGS) proteins act as GTPase-activating proteins (GAPs) for ␣ subunits of heterotrimeric G-proteins. Previous in situ hybridization analysis of mRNAs encoding RGS3-RGS11 revealed region-specific expression patterns in rat brain. RGS9 showed a particularly striking pattern of almost exclusive enrichment in striatum. In a parallel study, RGS9 cDNA, here referred to as RGS9-1, was cloned from retinal cDNA libraries, and the encoded protein was identified as a GAP for transducin (G␣ t ) in rod outer segments. In the present study we identify a novel splice variant of RGS9, RGS9-2, cloned from a mouse forebrain cDNA library, which encodes a striatal-specific isoform of the protein. RGS9-2 is 191 amino acids longer than the retinal isoform, has a unique 3Ј untranslated region, and is highly enriched in striatum, with much lower levels seen in other brain regions and no expression detectable in retina. Immunohistochemistry showed that RGS9-2 protein is restricted to striatal neuropil and absent in striatal terminal fields. The functional activity of RGS9-2 is supported by the finding that it, but not RGS9-1, dampens the G i/o -coupled -opioid receptor response in vitro. Characterization of a bacterial artificial chromosome genomic clone of ϳ200 kb indicates that these isoforms represent alternatively spliced mRNAs from a single gene and that the RGS domain, conserved among all known RGS members, is encoded over three distinct exons. The distinct C-terminal domains of RGS9-2 and RGS9-1 presumably contribute to unique regulatory properties in the neural and retinal cells in which these proteins are selectively expressed.

No abstract